EPE treatment increased p-AMPK/AMPK expression levels in both skeletal muscles and the livers but lowered the hepatic p-mTORC1/t-mTORC1 and p-p70S6K1 (Thr389)/t-p70S6K1 (Thr389) expressions, accompanied by decreased SREBP1C, SREBP2, FAS, and PPARγ expressions, but enhanced PPARα expressions, as a consequence of lowering blood TG and TC levels and improving insulin resistance. The gene discussed is FAS; the disease is Insulin resistance.